NASDAQ · AKTS
Healthcare · Biotechnology
$24.07
Up+$0.07 (+0.29%)
Updated Aug 22, 2026, 5:37 PM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
AKTS closed at $24.07 after 21 trading sessions, up 0.75% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $24.33 | $25.00 | $24.00 | $24.07 | 226.36K |
| Aug 20, 2026 | $24.75 | $24.75 | $23.4374 | $24.00 | 253.62K |
| Aug 19, 2026 | $26.28 | $26.28 | $24.42 | $25.02 | 216.57K |
| Aug 18, 2026 | $24.55 | $25.06 | $24.28 | $25.00 | 183.98K |
| Aug 17, 2026 | $24.89 | $24.89 | $24.11 | $24.72 | 163.13K |
| Aug 14, 2026 | $23.97 | $25.10 | $23.45 | $24.93 | 229.79K |
| Aug 13, 2026 | $24.37 | $24.5675 | $23.65 | $23.79 | 156.31K |
| Aug 12, 2026 | $25.00 | $25.305 | $23.865 | $24.00 | 213.79K |
| Aug 11, 2026 | $24.79 | $25.01 | $23.86 | $24.77 | 209.24K |
| Aug 10, 2026 | $24.07 | $25.27 | $23.78 | $24.10 | 240.09K |
| Aug 7, 2026 | $24.07 | $24.55 | $23.82 | $24.13 | 154.84K |
| Aug 6, 2026 | $22.34 | $24.00 | $22.23 | $23.44 | 266.66K |
| Aug 5, 2026 | $23.02 | $23.48 | $22.50 | $22.65 | 248.42K |
| Aug 4, 2026 | $22.48 | $23.3199 | $22.24 | $22.84 | 299.23K |
| Aug 3, 2026 | $22.07 | $22.33 | $21.46 | $22.23 | 314.68K |
| Jul 31, 2026 | $23.04 | $23.14 | $21.34 | $22.07 | 278.44K |
| Jul 30, 2026 | $22.24 | $23.21 | $21.80 | $23.00 | 331.09K |
| Jul 29, 2026 | $23.05 | $23.48 | $22.27 | $22.39 | 314.93K |
| Jul 28, 2026 | $24.22 | $24.255 | $22.54 | $22.97 | 312.23K |
| Jul 27, 2026 | $24.16 | $25.20 | $24.16 | $24.21 | 258.79K |
| Jul 24, 2026 | $24.06 | $24.58 | $23.395 | $23.89 | 193.8K |
The latest Smart Investors Daily articles mentioning AKTS.
AKTS research
Company profile and research snapshot.
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. It has one operating segment focused on the research and development of targeted radiopharmaceuticals.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 19, 2026 | Wedbush | Outperform | — |
| Aug 19, 2026 | BMO Capital | Outperform | — |
| Jul 14, 2026 | JP Morgan | Overweight | — |
| Jun 16, 2026 | Raymond James | Strong Buy | — |
| Jun 2, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 19, 2026
Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $35.
Benzinga · Aug 19, 2026
BMO Capital analyst David Lebowitz initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $37.
Benzinga · Aug 13, 2026
Aktis Oncology (NASDAQ:AKTS) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 98.03 percent increase over losses of $(22.39) per share from
Benzinga · Jul 14, 2026
JP Morgan analyst Jessica Fye maintains Aktis Oncology (NASDAQ:AKTS) with a Overweight and raises the price target from $30 to $33.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AKTS.
